Moreover, upregulation of both BAG3 and MCL1 may have a negative effect toward MSC-TRAIL and apoptosis induction [131,132], and knocking down both genes through pre-treatment in NSCLC may sensitize the CD133+ CSCs to the effect of MSC-TRAIL-mediated inhibition. This evidence concerns the gene MCL1 and non-small cell lung carcinoma.